特發性肺纖維化生物標志物的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

楊紅嬌 , 董昭興 ,  王穎

昆明醫科大學第二附屬醫院呼吸內科（云南昆明 650101）;

Corresponding?author：

王穎, Email: w.y925@163.com

Keywords：

DOI：

10.7507/1671-6205.201806001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 楊紅嬌, 董昭興, 王穎. 特發性肺纖維化生物標志物的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 204-208. doi: 10.7507/1671-6205.201806001 Copy

1.	Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
2.	Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med, 2014, 35(2): 181.
3.	朱晨, 趙亞濱, 孔靈菲, 等. 涎液化糖鏈蛋白 6 在特發性肺纖維化患者支氣管肺泡灌洗液和血清中的表達及臨床意義. 中國呼吸與危重監護雜志, 2015, 14(3): 225-228.
4.	Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD, 2017, 14(2): 245-250.
5.	Sokai A, Handa T, Tanizawa K, et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res, 2015, 16(1): 120.
6.	Morais A, Beltr?o M, Sokhatska O, et al. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med, 2015, 109(8): 1063-1068.
7.	Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med, 2012, 106(4): 571-580.
8.	Seung-Ick C, Ryerson CJ, Lee JS, et al. Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir Res, 2012, 13(1): 1-9.
9.	Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2009, 179(8): 717-723.
10.	White ES, Meng X, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 2016, 194(10): 1242.
11.	中華醫學會呼吸病學分會間質性肺疾病學組. 特發性肺纖維化診斷和治療中國專家共識. 中華結核和呼吸雜志, 2016, 39(6): 427-432.
12.	Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med, 2014, 108(7): 1031.
13.	Kakugawa T, Yokota S, Ishimatsu Y, et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones, 2013, 18(5): 581-590.
14.	Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 2010, 299(1): L3.
15.	Kai W, Ju Q, Jing C, et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore), 2017, 96(23): e7083.
16.	Depianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax, 2015, 70(1): 48-56.
17.	Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2014, 189(8): 966.
18.	Reilkoff RA, Peng H, Murray LA, et al. Semaphorin 7a⁺ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med, 2013, 187(2): 180.
19.	Hou Z, Ye Q, Qiu M, et al. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 170.
20.	Wakamatsu K, Nagata N, Kumazoe H, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Invest, 2017, 55(1): 16.
21.	Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med, 2014, 190(7): 773-779.
22.	Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res, 2017, 3(3): 00019-2016.
23.	Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest, 2009, 135(6): 1557-1563.
24.	Takahashi H, Shiratori M, Kanai A, et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology, 2006, 11(Suppl): S51-S54.
25.	Stanley SE, Armanios M. Short telomeres: a repeat offender in IPF. Lancet Respir Med, 2014, 2(7): 513.
26.	Dai J, Cai H, Zhuang Y, et al. Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population. Respirology, 2015, 20(1): 122-128.
27.	Dai J, Cai H, Li H, et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology, 2015, 20(6): 947-952.
28.	Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 486-493.
29.	Okamoto M. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J, 2011, 37(5): 1119.
30.	Tajiri M, Okamoto M, Fujimoto K, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Invest, 2015, 53(2): 73.
31.	Ohta S, Okamoto M, Fujimoto K, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PloS One, 2017, 12(3): e0174547.
32.	van Moorsel CH, Hoffman TW, van Batenburg AA, et al. Understanding idiopathic interstitial pneumonia: a gene-based review of stressed lungs. Biomed Res Int, 2015, 2015: 304186.
33.	Jiang H, Hu Y, Shang L, et al. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. Int J Clin Exp Pathol, 2015, 8(11): 14953-14958.
34.	Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA, 2013, 309(21): 2232-2239.
35.	Molyneaux PL, Maher TM. Respiratory microbiome in IPF: cause, effect, or biomarker?. Lancet Respir Med, 2014, 2(7): 511-513.
36.	Molyneaux PL, Cox MJ, Willisowen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2013, 190(8): 906-913.
37.	Han MLK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med, 2014, 2(7): 548-556.
38.	Huang Y, Ma SF, Espindola MS, et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2017, 196(2): 208.
39.	Molyneaux PL, Cox MJ, Wells AU, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 29.
40.	Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest, 2015, 125(2): 521-538.
41.	Aggarwal S, Mannam P, Zhang J. Differential regulation of autophagy and mitophagy in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol, 2016, 311(2): L433.
42.	Ryu C, Sun H, Gulati M, et al. Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2017, 196(12): 1571-1581.

1. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
2. Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med, 2014, 35(2): 181.
3. 朱晨, 趙亞濱, 孔靈菲, 等. 涎液化糖鏈蛋白 6 在特發性肺纖維化患者支氣管肺泡灌洗液和血清中的表達及臨床意義. 中國呼吸與危重監護雜志, 2015, 14(3): 225-228.
4. Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD, 2017, 14(2): 245-250.
5. Sokai A, Handa T, Tanizawa K, et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res, 2015, 16(1): 120.
6. Morais A, Beltr?o M, Sokhatska O, et al. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med, 2015, 109(8): 1063-1068.
7. Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med, 2012, 106(4): 571-580.
8. Seung-Ick C, Ryerson CJ, Lee JS, et al. Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir Res, 2012, 13(1): 1-9.
9. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2009, 179(8): 717-723.
10. White ES, Meng X, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 2016, 194(10): 1242.
11. 中華醫學會呼吸病學分會間質性肺疾病學組. 特發性肺纖維化診斷和治療中國專家共識. 中華結核和呼吸雜志, 2016, 39(6): 427-432.
12. Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med, 2014, 108(7): 1031.
13. Kakugawa T, Yokota S, Ishimatsu Y, et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones, 2013, 18(5): 581-590.
14. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 2010, 299(1): L3.
15. Kai W, Ju Q, Jing C, et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore), 2017, 96(23): e7083.
16. Depianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax, 2015, 70(1): 48-56.
17. Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2014, 189(8): 966.
18. Reilkoff RA, Peng H, Murray LA, et al. Semaphorin 7a⁺ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med, 2013, 187(2): 180.
19. Hou Z, Ye Q, Qiu M, et al. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 170.
20. Wakamatsu K, Nagata N, Kumazoe H, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Invest, 2017, 55(1): 16.
21. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med, 2014, 190(7): 773-779.
22. Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res, 2017, 3(3): 00019-2016.
23. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest, 2009, 135(6): 1557-1563.
24. Takahashi H, Shiratori M, Kanai A, et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology, 2006, 11(Suppl): S51-S54.
25. Stanley SE, Armanios M. Short telomeres: a repeat offender in IPF. Lancet Respir Med, 2014, 2(7): 513.
26. Dai J, Cai H, Zhuang Y, et al. Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population. Respirology, 2015, 20(1): 122-128.
27. Dai J, Cai H, Li H, et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology, 2015, 20(6): 947-952.
28. Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 486-493.
29. Okamoto M. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J, 2011, 37(5): 1119.
30. Tajiri M, Okamoto M, Fujimoto K, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Invest, 2015, 53(2): 73.
31. Ohta S, Okamoto M, Fujimoto K, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PloS One, 2017, 12(3): e0174547.
32. van Moorsel CH, Hoffman TW, van Batenburg AA, et al. Understanding idiopathic interstitial pneumonia: a gene-based review of stressed lungs. Biomed Res Int, 2015, 2015: 304186.
33. Jiang H, Hu Y, Shang L, et al. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. Int J Clin Exp Pathol, 2015, 8(11): 14953-14958.
34. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA, 2013, 309(21): 2232-2239.
35. Molyneaux PL, Maher TM. Respiratory microbiome in IPF: cause, effect, or biomarker?. Lancet Respir Med, 2014, 2(7): 511-513.
36. Molyneaux PL, Cox MJ, Willisowen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2013, 190(8): 906-913.
37. Han MLK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med, 2014, 2(7): 548-556.
38. Huang Y, Ma SF, Espindola MS, et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2017, 196(2): 208.
39. Molyneaux PL, Cox MJ, Wells AU, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 29.
40. Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest, 2015, 125(2): 521-538.
41. Aggarwal S, Mannam P, Zhang J. Differential regulation of autophagy and mitophagy in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol, 2016, 311(2): L433.
42. Ryu C, Sun H, Gulati M, et al. Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2017, 196(12): 1571-1581.

Previous Article
特發性肺纖維化治療新進展

Chinese Journal of Respiratory and Critical Care Medicine

特發性肺纖維化生物標志物的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content